Trevi up as lung therapy meets main goal in mid-stage study

Trevi Finanziaria Industriale SpA

19/09/2022 13:23

** Drug Developer Trevi Therapeutics Inc's shares  TRVI.O 
rise 8% to $3.52 before the bell
    ** Co says its investigational therapy for the treatment of
chronic cough in adults with idiopathic pulmonary fibrosis met
main goal in mid-stage study  urn:newsml:reuters.com:*:nPn3YJb3Ta
    ** The therapy, when compared to placebo achieved
statistically significant reduction in cough frequency in
patient 
    ** Idiopathic pulmonary fibrosis is a serious chronic
disease that affects the tissue surrounding the air sacs, or
alveoli, in lungs making it difficult to breathe over time - NIH
    ** Up to Friday's close, stock has more than doubled YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))